SCHEMBL7081932

SCHEMBL7081932

CCn1cc2c(=O)n(Cc3ccccn3)cnc2n1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
KDM4E B2RXH2 10/20 0.47
ALDH1A1 P00352 8/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GLA P06280 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
GAA P10253 1/20 0.43
CNOT7 Q9UIV1 1/20 0.42
MAPK1 P28482 1/20 0.41
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
GABRA5 P31644 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081641 0.91 LMNA (0.47) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7077256 0.87 LMNA (0.51) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7081274 0.85 LMNA (0.51) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7077332 0.82 LMNA (0.48) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7082149 0.81 LMNA (0.59) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7000049 0.81 SMN1; SMN2 (0.44) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL12672889 0.80 USP19 (0.41) ALDH1A1SMN1; SMN2
SCHEMBL7081643 0.78 TSHR (0.45) LMNAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7083472 0.78 LMNA (0.47) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL7002562 0.76 KDM4E (0.53) LMNAKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US claimed
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same DDO, GRIN3A, GRIK4 LMNA 1746/4885KDM4E 1874/4885ALDH1A1 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.